Global net revenues from the hematologic oncology portfolio were $1.13B, an increase of 50.2% on a reported basis; global IMBRUVICA net revenues were $1.006B, an increase of 42%; global VENCLEXTA net revenues were $124M. Fourth-quarter global HCV net revenues were $862M.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.